Cargando…
The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer’s Disease
Amyloid-beta (Aβ) deposition in the brain is closely linked with the development of Alzheimer’s disease (AD). Unfortunately, therapies specifically targeting Aβ deposition have failed to reach their primary clinical endpoints, emphasizing the need to broaden the search strategy for alternative targe...
Autores principales: | Wilhelmus, Micha M. M., Tonoli, Elisa, Coveney, Clare, Boocock, David J., Jongenelen, Cornelis A. M., Brevé, John J. P., Verderio, Elisabetta A. M., Drukarch, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834516/ https://www.ncbi.nlm.nih.gov/pubmed/35159198 http://dx.doi.org/10.3390/cells11030389 |
Ejemplares similares
-
Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice
por: Wilhelmus, Micha M. M., et al.
Publicado: (2022) -
Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018) -
Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018) -
Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer’s disease mouse models
por: Wilhelmus, Micha M. M., et al.
Publicado: (2016) -
Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients
por: Sestito, Claudia, et al.
Publicado: (2018)